ERBB2 and breast carcinoma: A decade ago, other ADCs also entered clinical practice, such as Brentuximab vedotin (for Hodgkin lymphoma and anaplastic large cell lymphoma), Trastuzumab emtansine (for HER2-positive breast carcinoma), and Inotuzumab ozogamicin (for B-cell acute lymphoblastic leukemia) among others [20,23-26].